Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding sublingual and subcutaneous mite allergen immunotherapy for rhinitis/rhinoconjunctivitis
2015-000820-27Phase 2Active
- Sponsor
- Inmunotek
- Start
- Sep 2015
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dermatophagoides pteronyssinus + dermatophagoides farinae allergen extract in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and house dust mite allergy (5 arms), sponsored by Inmunotek. Primary endpoint: Change in nasal provocation threshold concentration by acoustic rhinometry. Started Sep 2015; status: active.
02
Drugs
dermatophagoides pteronyssinus + dermatophagoides farinae allergen extract
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)house dust mite allergy
Beyond the preview
Go deeper on 2015-000820-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000820-27.